FormalPara Key Summary Points

A comprehensive overview of published ocular side effects potentially associated with COVID-19 vaccination

Ocular phenomena post-COVID-19 vaccination may occur via an immune response elicited by the vaccine

COVID-19 vaccine-induced ocular (CVIO) adverse events could resemble the ocular findings in some COVID-19 patients

The ocular adverse events related to COVID-19 vaccines have a remarkably low incidence especially when considering the extremely large numbers of people that have been inoculated worldwide

It is often easily treated, and the worst cases are still not as bad as having the COVID-19 infection

This review could be beneficial to practicing ophthalmologists and clinicians in identifying patients who may be at a higher risk of ocular inflammation so that protocols for close monitoring and education of the patients at risk can be designed and implemented


Coronaviruses are ubiquitous and can affect several organs including the eye. Currently, there are a total of seven different strains of coronaviruses that infect humans. Common cold coronavirus strains include 229E (alphacoronavirus), NL63 (alphacoronavirus), OC43 (betacoronavirus) and HKU1 (betacoronavirus). On the other hand, pathogenic strains include MERS-CoV (betacoronavirus), SARS-CoV (betacoronavirus) and, most recently, SARS-CoV-2 [1]. Murine models have revealed a progressive retinal degeneration associated with autoimmune reactivity early after virus infection [2]. The disease was shown to be biphasic. During the initial infection, the virus and associated viral particles were found in both the retina and pigment epithelium that lasted a week, with retinal persistence and prolonged expression of ribonucleic acid (RNA) detected via in situ hybridization [3].

A chronic degenerative phase develops in susceptible strains such as BALB/c mice, leading to a progressive loss of photoreceptors, retinal pigment epithelium (RPE) and ganglion cells mediated, in part, by a reactivity to autoantigens [4]. It should therefore come as no surprise that coronaviruses can lead to both an acute ocular presentation and a more delayed immune-mediated response in susceptible humans.

In addition, in both experimental models and natural disease, SARS-CoV-2 has been associated with uveitis and ocular immune responses [5, 6]. Known ocular manifestations of COVID-19 infection include conjunctivitis, episcleritis, uveitis, vascular changes in the retina such as retinal hemorrhages, cotton wool spots, dilated veins and tortuous vessels, and optic neuritis, ocular motility deficits from cranial nerve palsies, ocular myasthenia gravis, acute dacryoadenitis and epiphora [7,8,9,10,11,12,13,14,15,16,17,18,19].

This review of the available literature provides an overview of ocular side effects possibly associated with COVID-19 vaccines. A review of the incidence of such conditions would be beneficial to practicing ophthalmologists and clinicians in identifying patients who may be at a higher risk of ocular adverse events so that protocols for close monitoring and education of the patients at risk can be designed and implemented [20].

This review adhered to the tenets of the Declaration of Helsinki, and as the research does not contain any patient data, specific ethical clearance was not required for this study based on our ethics committee guidelines. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

COVID-19 Vaccine-Associated Ocular Inflammation

Vaccines have been reported to induce ocular side effects, including conjunctival and eyelid reactions, optic neuritis and intraocular inflammation [21,22,23,24,25]. Furthermore, live attenuated vaccines may cause ocular infection from the organisms derived, especially in at-risk groups, including the immunosuppressed [26, 27]. The adjuvants included in COVID-19 mRNA vaccines stimulate innate immunity through endosolic or cytoplasmic nucleic acid receptors including Toll-like receptors (TLRs) [28]. Several autoimmune diseases, particularly connective tissues diseases, are associated with an altered nucleic acid metabolism and processing, which may trigger an immune response following immunization [29, 30]. Given the scale of the current vaccination campaign against COVID-19, acute and chronic inflammatory responses have been observed [31]. These include myocarditis [32], kidney transplant rejection [33] and vaccine-induced thrombotic thrombocytopenia (VITT) [34]. While cases of uveitis triggered or re-activated by SARS-CoV-2 have been described, there is a lack of literature describing possible failure of immune privilege or maladaptive immunity in response to COVID-19 vaccination in some susceptible individuals [35].

To date, there are numerous published and unpublished reports of ocular inflammation potentially associated with COVID-19 vaccination (Table 1). The COVID-19 vaccines include the mRNA vaccine (BNT162b2, Pfizer-BioNTech; mRNA-1273, Moderna), protein subunit vaccine (NVX-CoV2373, Novavax), vector vaccine (Ad26COVS1, Janssen Johnson & Johnson; AZD1222, Oxford-AstraZeneca) and whole virus (PiCoVacc, Sinovac; BBIBP-CorV, Sinopharm). In order of frequency of cases reported, where 'n' is the combined total number of subjects in the relevant studies for each category, the ocular complications reported were Bell's/facial nerve palsy (n = 30), central venous sinus thrombosis and thrombosis (n = 15), acute anterior uveitis (n = 9), acute macular neuroretinopathy (n = 8), corneal graft rejection (n = 6), anterior scleritis (n = 5), panuveitis (n = 4), posterior uveitis (n = 3), cranial nerve palsy (excluding Bell's/facial nerve palsy) (n = 1), central serous chorioretinopathy (n = 1), Vogt-Koyanagi-Harada disease (n = 2), central retinal vein occlusion (n = 1), bilateral multifocal choroiditis (n = 1), episcleritis (n = 1), intermediate uveitis (n = 1), paracentral acute middle maculopathy (n = 1), subretinal fluid (n = 1) and bilateral optic neuritis (n = 1), in a total of 89 subjects (Fig. 1). The reported entities appear to overlap with the ocular manifestation reported in patients infected with COVID-19, suggesting a common pathway (possibly TLR) between virus and vaccine-mediated immune response in humans. In addition, there are several unpublished reports of patients with uveitis post-COVID-19 vaccination. We will briefly describe some of the adverse effects reported following COVID-19 vaccination below.

Table 1 Overview of studies reported in the literature related to ocular side effects secondary to COVID-19 vaccination
Fig. 1
figure 1

Diagrammatic representation of the total number of subjects and different clinical presentations for post-COVID-19 vaccination ocular adverse events

Bell's/Facial Nerve Palsy

One study, part of the clinical trials for the BNT162b2 and mRNA-1273 vaccines, found a higher incidence of Bell's palsy in subjects receiving the vaccine (n = 7) than in those receiving placebo (n = 1) [36]. The time to the onset of symptoms was not mentioned. A case-control study found that in 21 patients against 44 unvaccinated controls who presented with facial nerve palsy and had received the BNT162b2 vaccine (first or second dose) 30 days prior, there was no significant difference in the occurrence of facial nerve palsy [37]. However, both studies did not include any details on ocular manifestations or ophthalmic investigations, nor did they provide visual outcomes of the patients. Another case report by Ish et al. reported a middle-aged male who developed facial nerve palsy 3 weeks after receiving the second dose of COVAXIN [38]. He was treated with a tapering dose of oral prednisolone at 1 mg/kg for 2 weeks with improvement of presentation on review at day 10.

Superior Ophthalmic Vein Thrombosis

There is a published report of two patients with bilateral thrombosis of the superior ophthalmic vein in addition to rare cases of cerebral venous sinus thrombosis and vaccine-induced immune thrombocytopenia with consequential orbital symptoms and signs of inflammation [39,40,41]. Investigations performed to confirm thrombosis include computed tomography (CT), angiography of the head and neck and magnetic resonance imaging (MRI) of the brain. Of the 15 subjects with thrombosis reported in these three studies, 4 presented with ocular symptoms including conjunctival congestion, fixed and dilated pupil, gaze deviation, diplopia, retroorbital pain and unspecified visual changes. All four were female; two had additional risk factors for thrombosis, including obesity, hypothyroidism and oral contraceptive pill (OCP) usage. The subjects manifested symptoms between 6 and 17 days post-vaccination. Subjects received either the AZD1222 or Ad26COVS1 vaccines. Of note, the Ad26COVS1 was designed as a single-dose vaccine. None included detailed ophthalmic investigations, treatment, or visual outcomes of the subjects.

Acute Anterior Uveitis

Our local authors (unpublished data) reported seven cases of acute anterior non-granulomatous uveitis post-vaccination. Symptom onset ranged from 1 day to 1 month after receiving the first or second dose of the BNT162b2 or mRNA-1273 vaccine. Similarly, El Sheikh et al. reported one cases of acute uveitis following vaccination with the BBIBP-CorV vaccine [42]. The female subject presented 5 days following the second dose of the vaccine with acute onset of bilateral blurred vision and photophobia and was diagnosed with juvenile idiopathic arthritis (JIA)-associated anterior uveitis that responded to topical corticosteroid treatment.

Acute Macular Neuroretinopathy (AMN)

Four female subjects presented with scotomas. All were on oral contraceptive pills (OCP) and manifested symptoms 2 days after the first dose of the vaccine [43,44,45]. Three reported fever, and one reported flu-like symptoms prior to the appearance of the scotoma. In two patients, the visual symptoms lasted < 24 h. On OCT, hyperreflectivity of the outer nuclear and plexiform layers was seen along with disruption of the ellipsoid zone. Subtle capillary dropout was also noted on angiography. All subjects received the AZD1222 vaccine. In another case report, Valenzuela et al. reported a case of a young female subject who presented with bilateral scotoma and photopsia 48 h after receiving the second dose of the BNT162b2 vaccine [46]. The subject was using an etonogestrel/ethinyl estradiol 0.12–0.015 mg/24 h vaginal ring for birth control. OCT demonstrated parafoveal foci of hyperreflectivity of the outer nuclear layer and granularity of the ellipsoid. Her symptoms resolved completely a week later.

Corneal Graft Rejection

There were two reported cases of allograft rejection following Descemet’s membrane endothelial keratoplasty (DMEK); both were female and had had grafts performed 21 days and 6 years before vaccine administration [47]. With a notable history of well-controlled human immunodeficiency virus infection with undetectable viral load, one subject manifested symptoms 7 days after the first dose of the vaccine. The other patient developed symptoms 3 weeks after the second dose. For both DMEK cases, slit-lamp examination and anterior optical coherence tomography (OCT) revealed moderate conjunctival injection, diffuse corneal edema and fine keratic precipitates limited to the donor endothelium with anterior chamber cells. Rejections were also reported following three penetrating keratoplasty (PKP) cases; all three were male; 1 case had a previous re-graft. Two of the PKP rejections manifested 13–14 days after the patients received the first dose of the vaccine, while the third occurred after 21 days, also from the first dose [48, 49]. The two DMEK and two of the three PKP rejections were treated successfully with oral and topical corticosteroids. Vaccines received by the subjects included the BNT162b2 and AZD1222 vaccines. In addition, Rallis et al. reported a case of a 68-year-old female subject who presented with left eye corneal graft failure 4 days after receiving the first dose of the BNT162b2 vaccine [50]. She had a history of bilateral Descemet stripping automated endothelial keratoplasty (DSAEK) for Fuchs’ corneal endothelial dystrophy and a left repeat penetrating keratoplasty (PKP) for failed DSAEK in October 2020. Slit-lamp examination revealed conjunctival hyperemia, corneal graft edema, diffuse corneal punctate staining, Descemet’s folds, scattered keratic precipitates and anterior chamber activity. Her right eye graft remained healthy. She was treated with intensive topical corticosteroids to her left eye and oral acyclovir to cover any underlying herpetic keratitis. Graft rejection resolved completely 3 weeks post-treatment.

Anterior Sclerites

Several cases of post-vaccination anterior scleritis have been reported. From our unpublished data, there have been three cases of diffuse anterior non-necrotizing anterior uveitis in female subjects 1 to 4 days after receiving the second dose of BNT162b2. The subjects’ symptomatic decrease in visual acuity resolved after receiving topical corticosteroids and additional oral NSAIDs in one subject. Pichi et al. reported two cases of anterior scleritis after receiving the BBIBP-CorV vaccine [51]. One patient presented with pain and redness in both eyes 1 week after receiving a dose of the vaccine, which resolved after a tapering dose of topical steroids.


Several case reports were identified. The first case was of a male patient with a prior SARS-COV-2 infection several months earlier who developed transient visual field loss 3 days after a first dose of BNT162b2 [52]. The visual acuity deficit lasted less than a day and was associated with perceived reduction of visual fields, a unilateral headache, nausea, asthenia and mild confusion. There was no further investigation. The second case concerned a female subject who on examination was found to have panuveitis [53]. She developed symptoms 3 days after the second dose. She underwent weekly nasopharyngeal swab tests for COVID-19 infection as part of her occupation’s routine required testing, of which only one was positive, with subsequent tests being negative. She neither manifested any symptoms of COVID-19 nor had a history of exposure to COVID-19 patients. Her vision of 20/500 in both eyes improved to 20/20 on a tapering dose of systemic corticosteroids, starting at 50 mg/day of oral prednisone and 2 hourly difluprednate lasting 3 weeks. At the end of 3 weeks, there was recurrence of choroidal thickening, and systemic corticosteroid therapy was recommenced at the time of publication. OCT was performed, which showed vitreous debris and retinal and choroidal thickening. Fluorescein angiography (FA) revealed mild peripheral vascular leakage. MRI brain and orbits with contrast were unremarkable. Both subjects had received the BNT162b2 vaccine.

Posterior Uveitis

Two female subjects presented to a local institution in Singapore (unpublished data) with posterior uveitis 3–6 weeks after receiving the second dose of BNT162b2. One subject presented with a scotoma and photopsia in the left eye while the other was found to have retinal dysfunction and papillitis. Their symptoms resolved upon receiving corticosteroids. One male patient also presented with decreased visual acuity 7 days after receiving the first dose of mRNA-1273, which was diagnosed as posterior uveitis. His symptoms resolved after the administration of oral and topical corticosteroids.

Cranial Nerve Palsy (Excluding Bell's/Facial Nerve Palsy)

A healthy female who received the BNT162b2 vaccine and presented with isolated abducens nerve palsy 2 days post-vaccination was reported [54]. No details on the persistence of the palsy were provided in the report. Examinations of the patient through slit-lamp, fundus examination and MRI brain and orbits without contrast were unremarkable.

Central Serous Retinopathy

Sixty-nine hours after receiving the first dose of the BNT162b2 vaccine, a 33-year-old male subject with a previous history of mild refractive hyperopic refractive error presented with blurring of vision and metamorphopsia and was subsequently diagnosed with central serous retinopathy [55]. Fundus examination revealed loss of foveal reflex and a swollen macula without hemorrhage. Further investigations such as imaging were performed. OCT revealed macular serous detachment of the neurosensory retina. In the area of serous retinal detachment, OCT angiography showed general attenuation of choriocapillaris flow signal while FA showed point leakage. After a course of spironolactone, all the patients’ symptoms resolved on follow-up.

Vogt-Koyanagi-Harada (VKH)

A female patient with a 6-year history of well-controlled VKH presented with a severe reactivation of VKH 6 weeks after receiving the second dose of the BNT162b2 vaccine. The initial onset of her VKH had been severe, which necessitated infliximab infusions as acute and maintenance therapy. Prior to the vaccinations, the patient had received infliximab infusions 3.5 weeks before the first vaccine dose and 7.5 weeks before the second vaccine dose [40]. Slit-lamp examination revealed anterior chamber inflammation with mutton-fat keratic precipitates. Furthermore, retinal folds, subretinal fluid and increased choroidal thickness were seen on OCT imaging. After the initiation of oral corticosteroids and infliximab therapy, the VKH disease reactivation was controlled. In a separate report, a 54-year-old male patient with no history of ocular disease presented with acute bilateral painless blurring of vision a week after receiving the first dose of the BNT162b2 vaccine. Clinical examination and imaging investigations were consistent with and led to the diagnosis of Vogt-Koyanagi-Harada disease. After an initial course of high-dose intravenous methylprednisolone and subsequent oral prednisolone, the patient’s symptoms resolved [41].

Central Retinal Vein Occlusion

Bialasiewicz et al. reported a case of central retinal vein occlusion post-vaccination in an otherwise previously healthy 50-year-old male patient [56]. During the 15-min surveillance period after receiving the second dose of BNT162b2, the patient developed retrobulbar pain, red eye and decreased vision in his left eye, which was eventually found to be caused by a central retinal vein occlusion. Investigations that were done, such as a thrombophilia panel, complete blood count and D-dimer levels, were unremarkable.

Bilateral Multifocal Choroiditis

Goyal et al. reported a case of bilateral choroiditis in a 34-year-old male patient post-vaccination [57]. One week after the second dose of AZD1222, the patient presented with severe vision loss of his right eye. Examination revealed a large serous detachment of the macula of the right eye. Additionally, ultrasonographic evaluation showed choroidal thickening in both eyes. After completing a 2-week course of oral corticosteroids, the patient made complete visual recovery.


Pichi et al. reported a case of episcleritis in a patient who had previously received the BBIBP-CorV vaccine. However, further details of the case were not reported [51].

Intermediate Uveitis

Our authors have seen a case of intermediate uveitis in a 50-year-old female patient following vaccination. Nine days after receiving the first dose of BNT162b2, the patient experienced an exacerbation of her existing intermediate uveitis complicated by cystoid macular edema.

Paracentral Acute Middle Maculopathy

A case of paracentral acute middle maculopathy was reported by Pichi et al. [51]. Twenty minutes after receiving the BBIBP-CorV vaccine, the patient had developed tachycardia, raised systolic blood pressure and an inferior scotoma of the left eye. Fundus examination revealed a dot hemorrhage superior to the fovea, and OCT angiography revealed superior enlargement of the foveal avascular zone.

Subretinal Fluid

Pichi et al. reported a case of subretinal fluid in a patient who had previously received the BBIBP-CorV vaccine. However, further details of the case were not reported [48].

Bilateral Optic Neuritis

A case of acute thyroiditis and bilateral optic neuritis following vaccination was reported by Leber et al. [58]. Twelve hours after receiving the second dose of PiCoVacc, a 32-year-old female experienced rapidly progressive decreased visual acuity, pain on movement of the left eye and headache. Furthermore, the patient experienced loss of temporal visual field of the left eye. Best corrected visual acuity was found to be 20/200 in the left eye, while this was preserved at 20/20 in the right eye. Fundus examination revealed bilateral disc swelling that was more prominent in the left eye. Subsequent work-up for raised intracranial pressure, demyelinating disease, intracranial infection and inflammatory disease was unremarkable. The patient was then diagnosed with vaccination-related bilateral optic neuritis and treated with intravenous corticosteroids, with subsequent improvement in visual acuity.

Graves' Disease

Two cases of Graves' disease (GD) post-vaccination were reported. One patient had a past medical history of a prior COVID-19 infection and pulmonary arterial hypertension. Both patients received the first dose of the BNT162b2 vaccine and reported their symptoms 2 to 3 days after and were subsequently diagnosed with Graves’ disease [59]. Biochemical studies including thyrotropin (TSH), thyroxine and triiodothyronine, antithyroid peroxidase, antithyroglobulin, anti-TSH and anti-TSH antibodies were performed, and the tests indicated active GD. The study did not include any description of ocular symptoms or ophthalmic investigations. Both patients’ presentations fit the diagnostic criteria for autoimmune/inflammatory syndrome induced by adjuvants (ASIA), which is also known as Shoenfeld's syndrome[28, 60].

Possible Mechanistic Insights and Impact

To increase the magnitude and efficacy of vaccines, adjuvants are added, which are meant to potentiate vaccine-mediated immune responses. While adjuvants are generally efficacious and safe, the administration of adjuvants may lead to autoimmune/inflammatory syndrome in a fraction of predisposed or genetically susceptible individuals (Fig. 2). According to WHO, about 185 COVID-19 vaccines are being explored in laboratory experiments and in animal models. About 114 vaccines are at various stages of Phase I–IV clinical trials. With extensive worldwide vaccination programs, few adverse events have been reported thus far. At present, there are four different types of COVID-19 vaccines. All four classes of COVID-19 vaccines have been under various stages of clinical trial (summarized in Fig. 3).

Fig. 2
figure 2

A possible hypothesis for post COVID-19 vaccination-associated ocular inflammation: illustration of the potential role of adjuvants in post-vaccination inflammation in genetically susceptible and predisposed subjects

Fig. 3
figure 3

Pie chart showing the development of COVID-19 vaccines at various stages (Phase I–III) of clinical trials (as of January 2021) and their classifications

Vaccine-associated uveitis (VAU) have been reported with almost all vaccines to date: hepatitis B vaccine, HPV vaccine, influenza vaccine, BCG vaccine, measles, mumps and rubella (MMR) and varicella vaccine [61]. Apart from reaction to adjuvants, molecular mimicry between vaccine peptide fragments and uveal self-peptides and delayed hypersensitivity, leading to deposition of immune complexes, have been suggested as possible reasons for VAU [62]. Furthermore, possible antigenic mimicry of Spike protein with retinal peptides cannot be ruled out.

Since administered vaccines are not able to cause the disease in the recipient but can still induce an immune response against the infection, we hypothesize that ocular events post-COVID-19 vaccination involve an altered metabolism of RNA (Spike protein) in susceptible individuals and the induction of TLRs.

Regarding COVID-19 vaccination-induced corneal graft rejection, the induction of TLRs in murine models demonstrates a contribution to corneal graft rejection via Th1 immunity [63]. With persistence of RNA in susceptible individuals, TLRs on the ocular surface are activated, which may contribute to the rejection of allogeneic grafts (Fig. 4). We suggest considering closer follow-up of corneal graft patients post-vaccination to allow for monitoring of graft health and the institution of earlier treatment in the event of rejection. The role of prophylactic corticosteroids may be appraised as well. This would serve to reduce the chance of graft loss and poorer visual outcomes, though it must be balanced against the side effects of systemic corticosteroid usage. In this time of the pandemic, rescheduling of nonurgent corneal graft surgery may also be considered.

Fig. 4
figure 4

Illustration of the possible path/mechanism of corneal graft rejection post-COVID-19 vaccination

AMN is a rare retinal disease, the pathophysiology of which is still unknown, although a microvascular abnormality in the deep capillary plexus of the retina is hypothesized. Of the AMN cases reviewed, all four subjects had the confounder of OCP usage. However, the relative rarity of AMN and the temporal association between the vaccine administration and onset of the disease should be considered. OCP usage has been associated with structural changes to the macula, retinal nerve fiber layer and choroidal thickness [64] and identified as a risk factor for AMN. This is likely due to the presence of estrogen and progesterone receptors in ocular tissues of premenopausal women, including the choroid and retina [65]. It has been postulated that concurrent OCP usage may increase the susceptibility of ocular tissues to AMN. Whether the potential thrombogenic role of COVID-19 vaccination played an additional role in the AMN pathogenesis of these patients has yet to be established (Fig. 5).

Fig. 5
figure 5

Illustration of onset of acute macular neuroretinopathy following COVID-19 vaccination—a possible mechanism

Regarding uveitis, it is interesting to note a similar timeline between the presentation of the case report mentioned above and that of a confirmed COVID-19 infected patient [10]. Of note, both the post-vaccination and the infected cases presented acutely within 2 weeks. Furthermore, bilateral anterior uveitis as a component of a multisystem inflammatory response to COVID-19 has been reported as well as a COVID-19 patient presenting with VKH [66, 67]. This lends credence to the theory that the inflammation is secondary to the innate immune response and that susceptible individuals may have altered RNA metabolism and overactivity of TLRs (as in VKH) that is triggered by the virus or the vaccine [59].

Concerning CSVT and thrombosis cases, we suggest a closer review of the temporal relation between the vaccine administration and ocular thromboembolic pathology, for instance, with retinal vein occlusion (RVO). RVO has been reported in previously healthy COVID-19 patients [68]. With the establishment of VITT, it would not be surprising if more reports on ocular thromboembolic phenomena are written in the future.

Patients with autoimmune disease (AID) are in a pro-inflammatory state with a predisposition to ocular inflammation such as retinitis and maculopathy [69]. We have included the report on Graves’ disease above for this purpose, especially as Graves’ is known to be associated with ophthalmopathy, which may be the first clinical presentation of the disease. Proposed mechanisms that contribute to AID flares post-vaccination include molecular mimicry, direct inflammatory insult, deposition of immune-complement complexes because of vaccine adjuvants (as with ASIA) and antigenic cross-reactivity [70,71,72,73]. As described in the introduction, the abnormal metabolism of RNA and induction of TLRs in susceptible individuals should also be considered. As more information is revealed about the details of the mechanisms involved, we hope that susceptible populations may be identified and preemptively screened. Consideration should also be given to Graves' disease patients post-vaccination, with the advice given to monitor for reactivation of the disease. Patient education and collaboration between the primary endocrinologist/physician and the ophthalmologist involved in managing a patient's Graves' disease are crucial for early detection of signs and symptoms and early treatment. As with corneal graft patients, a review on prophylactic treatment might be beneficial for patients.

A corollary to consider is vaccine response in patients with autoimmune disease [73]. Vaccinations in the autoimmune population decrease the burden of infection. However, with the above, the consequences of maladaptive immune response in those with autoimmune disease resulting in reactivation of disease (as with VKH) should be considered. It is then essential to establish the response of autoimmune disease patients to vaccines and whether the response is suboptimal in this population. This would have far-reaching consequences for future development of vaccines and risk stratification of at-risk groups.

We would like to acknowledge limitations in the review above. This article represents an effort to consolidate reported vaccine-associated adverse ocular events to date. As such, the inclusion criteria are numerous to capture an overview of the variety in presentation regarding ocular adverse events associated with vaccination that may first present to the ophthalmic setting. With variations in availability of vaccines, international approaches to vaccination campaigns and the nature of the studies reviewed—mostly case reports—there is significant heterogeneity in terms of assessment of patients and consolidation of cases deemed related to COVID-19 vaccination. In this article, we propose that certain individuals are genetically predisposed to vaccine-induced ocular adverse events. It is our hope that the article will serve as a springboard for more refined and standardized investigations regarding adverse ocular events post-vaccination.


The COVID-19 vaccines discussed in this review are relatively new. Much of the reviewed literature consisted of case reports and case series. Many reports provided limited details regarding ophthalmic examination, imaging, treatment and visual outcomes of patients. Notwithstanding the variation in details, such case reports represent possible ocular side effects associated with COVID-19 vaccines. More data on their side effects are emerging each day, and our knowledge on these side effects is still expanding. Given the nascent nature of these vaccines, we are unable to establish any causality in this review. Moreover, most cases of ocular side effects post-vaccination that were reviewed in this article saw swift recovery following the initiation of treatment. It is worth drawing attention to the fact that these adverse events related to COVID-19 vaccines have a remarkably low incidence. This is especially so when considering the extremely large numbers of people that have been inoculated around the world. Currently, there is no evidence to suggest that any special ophthalmic population has contraindications to vaccination.

This review article precedes a multicenter study on possible ocular associations post-COVID-19 vaccination, and we will eventually be looking at potential biomarkers associated with intraocular inflammation in correlation with COVID-19 vaccination. Implementation of a dedicated ophthalmic registry or establishing an ophthalmic division of existing registries for compilation and profiling of cases will further deepen our understanding of comorbidities associated with ocular COVID-19 infection and vaccination. These cases may then be reviewed and evaluated with more consistent protocols developed to assess and follow up future possibilities. This would aid in the establishment of risk factors as well (Fig. 6).

Fig. 6
figure 6

The eye of the storm: COVID-19 vaccination and ocular adverse events